In vivo methodology in behavioural pharmacology – Where are we now?

Janko Samardžić; Milica Borovčanin; Slavica Djukić Dejanović; Jasna Jančić; Miloš Djurić; Dragan I. Obradović

doi:10.2298/VSP150616106S

Janko Samardžić Institute of Pharmacology, Clinical Pharmacology and Toxicology, Faculty of Medicine, University of Belgrade, Belgrade, Serbia
Milica Borovčanin Department of Psychiatry, Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia; Psychiatric Clinic, Clinical Center Kragujevac, Kragujevac, Serbia
Slavica Djukić Dejanović Department of Psychiatry, Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia; Clinic for Psychiatric Disorders “Dr Laza Lazarević”, Belgrade, Serbia
Jasna Jančić Clinic of Neurology and Psychiatry for Children and Youth, Faculty of Medicine, University of Belgrade, Belgrade, Serbia
Miloš Djurić Institute of Pharmacology, Clinical Pharmacology and Toxicology, Faculty of Medicine, University of Belgrade, Belgrade, Serbia
Dragan I. Obradović Institute of Pharmacology, Clinical Pharmacology and Toxicology, Faculty of Medicine, University of Belgrade, Belgrade, Serbia

DOI: https://doi.org/10.2298/VSP150616106S

Keywords: pharmacology, disease models, behavior,

References

Samardžić J. Behavioural effects of the inverse agonists of ben-zodiazepine receptors. Beograd: Zadužbina Andrejević; 2015. (Serbian)

Mckinney WT. Animal models of depression: An overview. Psychiatr Dev 1984; 2(2): 77−96.

Fuchs E, Flugge G. Experimental animal models for the simula-tion of depression and anxiety. Dialogues Clin Neurosci 2006; 8(3): 323−33.

Wall P. Methodological and conceptual issues in the use of the elevated plus-maze as a psychological measurement instrument of animal anxiety-like behavior. Neurosci Biobehav Rev 2001; 25(3): 275−86.

Samardžić J, Savić K, Stefanović N, Matunović R, Baltezarević D, Obradović M, et al. Anxiolytic and antidepressant effect of zinc on rats and its impact on general behavioural parameters. Voj-nosanit Pregl 2013; 70(4): 391−5.

Abelaira HM, Réus GZ, Quevedo J. Animal models as tools to study the pathophysiology of depression. Rev Bras Psiquiatr 2013; 35(Suppl 2): S112−20.

Samardžić J, Jadžić D, Radovanović M, Jančić J, Obradović DI, Gojković-Bukarica LJ, et al. The effects of resveratrol on rat be-haviour in the forced swim test. Srp Arh Celok Lek 2013; 141(9−10): 582−5. (Serbian)

Samardžić J, Švob Štrac DO, Oprić D, Obradović DI. DMCM, a benzodiazepine site inverse agonist, improves active avoidance and motivation in the rat. Behav Brain Res 2012; 235(2): 195−9.

Samardžić J, Puškaš L, Obradović M, Lazić-Puškaš D, Obradović D. Antidepressant effects of an inverse agonist selective for α5 GABA-A receptors in the rat forced swim test. Acta Vet (Beo-grad) 2014; 64(1): 52−60.

Floresco SB, Geyer MA, Gold LH, Grace AA. Developing Predic-tive Animal Models and Establishing a Preclinical Trials Net-work for Assessing Treatment Effects on Cognition in Schi-zophrenia. Schizoph Bull 2005; 31(4): 888−94.

Floresco SB, Jentsch JD. Pharmacological enhancement of mem-ory and executive functioning in laboratory animals. Neurop-sychopharmacology 2011; 36(1): 227−50.

Savić MM, Clayton T, Furtmüller R, Gavrilović I, Samardžić J, Savić S, et al. PWZ-029, a compound with moderate inverse agonist functional selectivity at GABAA receptors containing α5 sub-units, improves passive, but not active avoidance learning in rats. Brain Res 2008; 1208: 150−9.

Craver C, Darden L. Discovering mechanisms in neurobiology: The case of spatial memory. In: Machamer PK, Grush R, Mclaughlin P, editors. Theory and method in the neurosciences. Pittsburgh: University of Pittsburgh Press; 2001. p. 112−37.

Zhang F, Zhu ZQ, Liu DX, Zhang C, Gong QH, Zhu YH. Emul-sified isoflurane anesthesia decreases brain-derived neuro-trophic factor expression and induces cognitive dysfunction in adult rats. Exp Ther Med 2014; 8(2): 471−7.

Paul CM, Magda G, Abel S. Spatial memory: Theoretical basis and comparative review on experimental methods in rodents. Behav Brain Res 2009; 203(2): 151−64.

Vorhees CV, Williams MT. Morris water maze: Procedures for assessing spatial and related forms of learning and memory. Nat Protoc 2006; 1(2): 848−58.

McNamara RK, Skelton RW. The neuropharmacological and neurochemical basis of place learning in the Morris water maze. Brain Res Rev 1993; 18(1): 33−49.

Terry AV Jr. Spatial Navigation (Water Maze) Tasks. In: Bucca-fusco JJ, editor. Methods of Behavior Analysis in Neuroscience. 2nd ed. Boca Raton (FL): CRC Press; 2009.

Lipska B. To Model a Psychiatric Disorder in Animals Schi-zophrenia As a Reality Test. Neuropsychopharmacology 2000; 23(3): 223−39.

Schizophrenia Research Forum. Animal Models for Schizophrenia Research 2014. [cited 2015 Apr 26]. Available from: http://www.schizophreniaforum.org/res/animal/animal_tables.asp

Marcotte ER, Pearson DM, Srivastava LK. Animal models of schizophrenia: A critical review. J Psychiatry Neurosci 2001; 26(5): 395−410.

Porsolt RD, Moser PC, Castagné V. Behavioral indices in antipsychotic drug discovery. J Pharmacol Exp Ther 2010; 333(3): 632−8.

Porsolt RD, Castagné V, Hayes E, Virley D. Nonhuman primates: translational models for predicting antipsychotic-induced movement disorders. J Pharmacol Exp Ther 2013; 347(3): 542−6.

Jentsch JD. Enduring Cognitive Deficits and Cortical Do-pamine Dysfunction in Monkeys After Long-Term Ad-ministration of Phencyclidine. Science 1997; 277(5328): 953−5.

Möhler H, Boison D, Singer P, Feldon J, Pauly-Evers M, Yee BK. Glycine transporter 1 as a potential therapeutic target for schi-zophrenia-related symptoms: evidence from genetically mod-ified mouse models and pharmacological inhibition. Biochem Pharmacol 2011; 81(9): 1065−77.

Geyer M, Moghaddamn B. Animal models relevant to schizoph-renia disorders. In: Davis K, Charney D, Coyle J, Nemeroff C, edi-tors. Neuropsychopharmacology: The Fifth Generation of Progress. Washington, DC: American College of Neuropsy-chopharmacology; 2002. p. 689−701.

Jackson-Lewis V, Blesa J, Przedborski S. Animal models of Par-kinson's disease. Parkinsonism Relat Disord 2012; 18(1): 183−5.

Bové J, Perier C. Neurotoxin-based models of Parkinson's dis-ease. Neuroscience 2012; 211: 51−76.

Klinkenberg I, Blokland A. The validity of scopolamine as a pharmacological model for cognitive impairment: a review of animal behavioral studies. Neurosci Biobehav Rev 2010; 34(8): 1307−50.

Sarter M. Preclinical research into cognition enhancers. Trends Pharmacol Sci 2006; 27(11): 602−8.

Albelda N, Joel D. Current animal models of obsessive compul-sive disorder: An update. Neuroscience 2011; 211: 83−106.

Sesia T, Bizup B, Grace AA. Evaluation of animal models of ob-sessive-compulsive disorder: Correlation with phasic dopamine neuron activity. Int J Neuropsychopharmacol 2013; 16(6): 1295−307.

Collins A, Hill LE, Chandramohan Y, Whitcomb D, Droste SK, Reul JM, et al Exercise Improves Cognitive Responses to Psycho-logical Stress through Enhancement of Epigenetic Mechan-isms and Gene Expression in the Dentate Gyrus. PLoS ONE 2009; 4(1): e4330.

Rudolph U, Mohler H. Genetically modified animals in pharma-cological research: Future trends. Eur J Pharmacol 1999; 375(1−3): 327−37.

Obradović D, Savić M, Ugrešić N, Bokonjić D. GABAA receptors: Molecular substrate for development of new anxiolytics. Voj-nosanit Pregl 2003; 60(3): 345−52. (Serbian)

Barnes NM, Sharp T. A review of central 5-HT receptors and their functions. Neuropharmacology 1999; 38(8): 1083−152.